Treats relapsing forms of multiple sclerosis (MS). ANDA 206873, held by Synthon. Glatiramer Acetate.
As of Nov 21, 2026, ANDA 206873 (Glatiramer Acetate), held by Synthon, was first approved by FDA on Sep 25, 2024, with 1 approved supplement and 0 published complete response letters.
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatiramer Acetate40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| May 16, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 25, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters